RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

PHASE3RecruitingINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

May 8, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Coronary Artery Disease
Interventions
DRUG

[O-15]-Water PET Myocardial Perfusion Imaging (MPI)

\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.

Trial Locations (13)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

22903

RECRUITING

University of Virginia Medical Center, Charlottesville

49503

WITHDRAWN

BAMF Healthcare, Grand Rapids

52242

RECRUITING

University of Iowa, Iowa City

55905

RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University, St Louis

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Unknown

RECRUITING

University of Ottawa Heart Institute, Ottawa

RECRUITING

Aarhus University Hospital, Aarhus

RECRUITING

University Hospital Freiburg, Clinic for Nuclear Medicine, Freiburg im Breisgau

RECRUITING

Department of Cardiology and Angiology, Hannover Medical School, Hanover

RECRUITING

Sahlgrenska University Hospital, Gothenburg

NOT_YET_RECRUITING

Norrland University Hospital Heart Center, Umeå

Sponsors
All Listed Sponsors
lead

MedTrace Pharma A/S

INDUSTRY